Compare Merck & Co., Inc. (MRK) vs Public Storage (PSA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Public Storage — how do they compare? Merck & Co., Inc. trades at $130.53 (market cap $323.00B), while Public Storage trades at $325.13 (market cap $60.82B). The key difference: Merck & Co., Inc. is far larger — about 5.3× Public Storage's market cap, and Public Storage pays the higher dividend (3.68%). Which is the better fit depends on your goals.
| MRK | PSA | |
|---|---|---|
Market Cap | $323.00B | $60.82B |
Sector | Health | Real Estate |
52-Week High | $131.84 | $330.47 |
52-Week Low | $77.60 | $258.44 |
Enterprise Value | $369.77B | $75.10B |
Dividend Yield | 2.6% | 3.68% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $130.41, up 1.43% today, with a bullish technical outlook supported by moving averages and a consensus price target of $139.90. The company reported strong earnings beats in recent quarters, with Q3 2026 EPS expected at $2.27. Revenue grew to $65.01B in 2025, and net income reached $18.25B, though 2026 projections show a decline. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives.
The stock presents a favorable risk-reward profile with analyst support (67.57% buy ratings) and institutional accumulation, but faces risks from patent expirations, competitive pressures, and macroeconomic volatility. Earnings sustainability and integration of acquisitions are key to maintaining momentum amid a high P/E ratio of 104.74.
Public Storage (PSA) trades at $328.40, up 0.43% on the day, with a bullish technical signal from moving averages and a consensus price target of $333.88. The company reported Q2 2026 EPS of $2.55, beating estimates, and raised full-year guidance following the acquisition of National Storage Affiliates. Strong profitability is evident with a net income margin of 41.8% and ROE of 37.42%, though valuation multiples like P/E of 31.34 suggest a premium.
Outlook remains positive due to accretive acquisitions and dividend stability, with a $3.00 quarterly dividend declared. Risks include high valuation, interest rate sensitivity, and integration challenges from recent deals. Analyst sentiment is mixed with 28.6% buy ratings, but institutional activity shows both position increases and cuts, indicating cautious optimism.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Public Storage
Public Storage is the largest owner of self-storage facilities in the U.S. with more than 2,800 self-storage facilities in 39 states and approximately 200 million square feet of rentable space. Through equity interests, it also has exposure to the European self-storage market through Shurgard Self Storage and to an additional 28 million net rentable square feet of industrial space in the United States through PS Business Parks.
Read more on PSA →
